Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation therapy shows promise for Tough-to-Treat prostate cancer

NCT ID NCT05114746

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 14, 2026 · Updated 20 times

Summary

This study tested a drug called 177Lu-PSMA-617, which delivers radiation directly to prostate cancer cells. It involved 94 men in Japan with advanced prostate cancer that had stopped responding to hormone therapy. The goal was to see if the drug could shrink tumors and control the disease, but it is not a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Kashiwa, Chiba, 277-8577, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 060-8648, Japan

  • Novartis Investigative Site

    Kobe, Hyōgo, 6500047, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 236-0004, Japan

  • Novartis Investigative Site

    Chiba, 260-8717, Japan

  • Novartis Investigative Site

    Fukushima, 9601295, Japan

  • Novartis Investigative Site

    Ishikawa, 9208641, Japan

  • Novartis Investigative Site

    Kyoto, 6068507, Japan

Conditions

Explore the condition pages connected to this study.

PROSTATE CANCER